Podcasts about cancer detection

AGNTCY - Unlock agents at scale with an open Internet of Agents. Visit https://agntcy.org/ and add your support.   What if AI could predict exactly when you'd get sick—and help you prevent it?   In this episode of Eye on AI, Dr. Eric Topol, world-renowned cardiologist, author, and AI health pioneer, joins us to unveil the future of preventive medicine. We dive deep into the themes of his new book Super Agers, which lays out a groundbreaking blueprint for extending healthspan—not just lifespan—through the power of multimodal AI and deep biological data.   Dr. Topol explains how AI models can now analyze a full-stack of human data—genomics, proteomics, metabolomics, microbiome, and more—to forecast age-related diseases like cancer, Alzheimer's, and heart disease decades before symptoms appear. This isn't science fiction. It's here now.   If you're interested in the intersection of AI, longevity, and the future of medicine, this is a must-listen.   Where AI Works tackles the big questions shaping AI's role in business today, cutting through the hype to deliver actionable insights for leaders. Brought to you by the Wharton School, in collaboration with Accenture, this podcast combines cutting-edge research with real-world case studies to uncover how top companies are using AI to upskill workforces, enhance customer experiences, boost productivity, and streamline operations.  Check it out:  https://link.cohostpodcasting.com/f5e223b4-da0c-4fc8-bbf3-5f24c15f8fd2?d=sxo9xhJN2    Stay Updated: Craig Smith on X:https://x.com/craigss Eye on A.I. on X: https://x.com/EyeOn_AI (00:00) The Power of Precision Medical Forecasting (01:53) Eric Topol's Journey into Digital & AI Medicine (03:27) Using AI to Prevent Aging-Related Diseases (05:25) The Challenge of Health Data Privacy & Ownership (09:05) Genetic Risk to Deep Data Insights (11:20) Personalized Prevention Through Lifestyle & Biomarkers (13:59) Why Anti-Aging Drugs Are Still Years Away (16:18) What are Organ Clocks (19:34) The Longevity Industry's Flawed Use of AI (21:59) Top AI Pioneers Endorse “Super Agers” (24:21) Which Longevity Startups Are Getting It Right? (26:27) Why Topol Refuses to Join Longevity Startups (28:57) Topol's Own Health Data & Lessons Learned (30:25) How Accurate Is AI at Predicting Disease Timing? (31:47) The Truth About Genetic Risk and Cancer Detection (33:33) AI-Driven Cancer Detection: A Smarter Approach (38:51) How Precision Medicine Has Evolved (41:02) The Risky Reality of Anti-Aging Interventions (44:39) Why Healthspan Matters More Than Lifespan

Navigating the intricate landscape of medical technology often involves overcoming substantial challenges, not just in device innovation but also in ensuring successful integration into healthcare systems. One significant hurdle is the adoption of new technologies by general practitioners, who require tools that are both effective and easy to integrate into their existing workflows without the complexities of specialist equipment. In this week's episode, sponsored by Physician Growth Accelerator, we are joined by Cody Simmons, co-founder and CEO of DermaSensor. Cody discusses DermaSensor, a revolutionary device that simplifies skin cancer detection, enabling general practitioners to diagnose with the accuracy of dermatologists. We delve into the story of DermaSensor, from its initial conception to achieving FDA clearance and the challenges faced in bringing this innovative technology to market. What we discuss in the episode: The development of DermaSensor and its impact on simplifying skin cancer detection for non-specialists. The barriers to technology adoption in healthcare, particularly issues around reimbursement and system integration. Strategies employed by DermaSensor to navigate regulatory hurdles and market challenges. Real-world benefits of the device in improving diagnostic accuracy and reducing healthcare inefficiencies. Resources from this episode:  Get the free MedTech Talk Tracks for Action Physician Growth Accelerator DermaSensor Social Media:  Connect with Cody on LinkedIn Connect with Zed on LinkedIn

In this episode of Menopause Mastery, I sit down with Sumit Rai, founder of Cancer Check Labs, to uncover a groundbreaking new approach to cancer screening and prevention. We dive deep into how cancer really develops—years before it's detectable by traditional scans—and why early detection at the cellular level could be the key to saving millions of lives. Sumit shares the powerful story behind his mission, the hidden dangers accelerating cancer rates (including toxins, diet, and lifestyle), and how standard treatments like chemo and surgery often miss the bigger picture. We also explore his revolutionary blood test that can find cancer cells before tumors become visible—and how new technologies like blood filtration could transform cancer care forever. If you're serious about proactive health, longevity, and protecting yourself and your loved ones, this is a must-listen conversation packed with science, hope, and action steps you can take today.  

In this episode of Menopause Mastery, I sit down with Sumit Rai, founder of Cancer Check Labs, to uncover a groundbreaking new approach to cancer screening and prevention. We dive deep into how cancer really develops—years before it's detectable by traditional scans—and why early detection at the cellular level could be the key to saving millions of lives. Sumit shares the powerful story behind his mission, the hidden dangers accelerating cancer rates (including toxins, diet, and lifestyle), and how standard treatments like chemo and surgery often miss the bigger picture. We also explore his revolutionary blood test that can find cancer cells before tumors become visible—and how new technologies like blood filtration could transform cancer care forever. If you're serious about proactive health, longevity, and protecting yourself and your loved ones, this is a must-listen conversation packed with science, hope, and action steps you can take today.  

In this episode of the Exploring AI in Oncology podcast, Waqas Haque, MD, MPH, a Hematology/Oncology Fellow at the University of Chicago, speaks with Samir Shah, MD, MMM, FACR, the Chief Medical Officer at Qure.ai. Their discussion explores how Qure.ai's innovative AI solutions are addressing critical gaps in lung cancer screening and improving early detection through advanced image analysis and clinical data integration.

Atzeyo Biosensors' platform helps doctors diagnose cancer in their offices.

Finding the right treatment for cancer is difficult at times, so how can computing power help us with this goal? Gabe Kwong, the Robert A. Milton associate professor of biomedical engineering at Georgia Tech University, examines. Gabe A. Kwong, Ph.D. is the Robert A. Milton Endowed Chair and Associate Professor of Biomedical Engineering at Georgia […]

BUFFALO, NY - April 8, 2025 – A new #editorial was #published in Oncotarget, Volume 16, on April 4, 2025, titled “Deep learning-based uncertainty quantification for quality assurance in hepatobiliary imaging-based techniques." Dr. Yashbir Singh from Mayo Clinic and his colleagues discussed how artificial intelligence (AI) can improve liver imaging by recognizing when it might be wrong. This approach, called “uncertainty quantification,” helps clinicians better detect liver cancer and other diseases by pointing out areas in medical scans that need a second look. The authors explain how these AI tools could make imaging results more accurate and reliable, which is especially important when diagnosing serious conditions like liver tumors. Liver and bile duct imaging is difficult because of the organ's complex structure and differences in image quality. Even skilled radiologists can struggle to identify small or hidden tumors, especially in patients with liver damage or scarring. The editorial explains how new AI models not only read medical images but also measure their own confidence. When the AI system is unsure, it can alert clinicians to take a closer look. This extra layer of information can reduce missed diagnoses and improve early detection of liver cancer. One of the most advanced tools described in the editorial is called AHUNet (Anisotropic Hybrid Network). This AI model works with both 2D and 3D images and can highlight which parts of a scan it is most confident about. It performed well when measuring the entire liver and showed how its confidence dropped when scanning smaller or multiple lesions. This feature helps clinicians know when more testing or review is needed. The authors also looked at other AI models used in liver imaging. Some tools were able to analyze liver fat using ultrasound images and give clinicians both a result and a confidence score. Others improved the speed and accuracy of liver magnetic resonance imaging (MRI) scans, helping to create clear images in less time. These advancements could help hospitals work faster and provide better care. The editorial highlights how this technology can be especially helpful in smaller clinics. If they do not have liver specialists, they could still use AI systems that flag uncertain results and send them to larger centers for review. Such an approach could improve care in rural or less-resourced areas. “Radiology departments should develop standardized reporting templates that incorporate uncertainty metrics alongside traditional imaging findings.” By using AI tools that know when to second-guess themselves, clinicians may soon have more reliable methods for detecting liver cancer and monitoring liver disease. The authors suggest that uncertainty-aware AI may soon become a vital part of everyday medical imaging, supporting faster and more accurate decisions in liver disease care. DOI: https://doi.org/10.18632/oncotarget.28709 Correspondence to: Yashbir Singh — singh.yashbir@mayo.edu Video short - https://www.youtube.com/watch?v=Zm0QASQ_YSI Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28709 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords: cancer, deep learning, uncertainty quantification, radiology, hepatobiliary imaging To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

In the wake of Atlantic editor-in-chief Jeffrey Goldberg's accidental inclusion in senior government officials' Signal group chat discussing war plans, Reid weighs in on how the U.S. government should—and shouldn't—use encrypted messaging apps. He and Aria also discuss AI-powered breakthroughs in cancer detection and medical diagnostics, along with NVIDIA's newly announced Superchip and OpenAI's latest image generation capabilities.  For more info on the podcast and transcripts of all the episodes, visit https://www.possible.fm/podcast/ 

Medical diagnostics saw a significant leap with an AI model demonstrating near-perfect cancer detection rates. In the tech industry, Google launched advanced real-time video AI features for Gemini, while Apple faced a lawsuit over delayed AI promises and explored integrating AI cameras into future Apple Watches. Government and infrastructure are also embracing AI, with the Trump administration launching a federal AI platform and Cape Town considering AI-powered traffic lights. Finally, the AI model landscape is evolving rapidly with DeepSeek releasing a major upgrade, and Perplexity making a bold bid to acquire TikTok's US operations.

Lung cancer is on the rise, even among those who have never smoked. Dr. Stephen Lam is a respirologist with the BC Cancer Research Centre, and has dedicated his career to lung cancer research and early detection. Stephen dives into the role of AI in predicting lung cancer risk and practical strategies to safeguard your lungs.

British tech company, Skin Analytics has received regulatory approval for DERM—its autonomous AI skin cancer detection system that uses a smartphone. Dermatologists are in short supply, with an average of only 30 dermatologists per one million population in Europe. Skin cancer is one of the most treatable forms of cancer if it's caught early but in the UK alone, NHS England says urgent skin cancer referrals have skyrocketed 170 percent in the last decade, and 11 percent of urgent cases wait over a month just to be seen. The simple app operates on most smartphones and with a lens attachment called a dermascope. It allows a technician to photograph a patient's lesion and receive an almost instantaneous diagnosis. The AI technology compares a single photograph of the lesion with a library of images before giving a diagnosis. Skin Analytics says DERM achieves a 99.8 percent accuracy rate in ruling out cancer. DERM was awarded the EU's Class III CE marked medical device under the European Medical Device Regulation, making it the world's first legally authorized autonomous AI for detecting cancer. It has already been deployed at 21 NHS (National Health Service) sites in the UK, racking up 135,000 patients assessed. More impressively still, it has helped to detect more than 13,000 cancers, according to Skin Analytics. "When you think about health care, it's a very human discipline. And at the end of the day, diagnostics is just one small part of the process. So by using technologies like DERM to be able to assess more patients, find the right patients to get into the dermatologist, we can really drive up the efficiency of our health care system and be able to see more patients faster and get them better outcomes," says Neil Daly, founder and CEO of Skin Analytics. DERM can automatically discharge up to 40 percent of urgent skin cancer referrals. It could become an important tool for early diagnosis of cancer and potentially save many lives. This article was provided by The Associated Press.

Physician Ash Alizadeh has seen the future of disease diagnosis and monitoring. It is coursing through every patient's veins. Traditionally, biopsies have required invasively gathering tissue – from a lung, a liver, or a fetus. Now it's possible to look for disease without surgery. The DNA is sitting there in the bloodstream, Alizadeh tells host Russ Altman, as they preview the age of liquid biopsies on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your quest. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Ash A. Alizadeh, MD/PhDConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Ash Alizadeh, a faculty member at Stanford University in Oncology and Medicine.(00:03:39) What is a Liquid Biopsy?Accessing tissues non-invasively using bodily fluids.(00:04:31) Detecting Cancer with Liquid BiopsiesHow localized cancers can be detected through blood samples.(00:06:32) The Science Behind Cancer DNA DetectionThe differences between normal and cancer DNA(00:09:51) How Liquid Biopsy Technology WorksThe technologies behind detecting cancer-related DNA differences.(00:12:36) Advances in Liquid BiopsyNew detection approaches using non-mutant molecules and RNA.(00:14:10) RNA as a Real-Time Tumor MarkerHow RNA reveals active tumor processes and drug resistance.(00:15:55) Tracking Cancer ReccurenceUsing tumor-informed panels to monitor cancer recurrence.(00:16:28)  Adapting to Tumor EvolutionWhy core mutations remain detectable despite cancer changes.(00:17:57) Stability of DNA, RNA, and MethylationComparing durability and reliability of different biomarkers.(00:20:49) Listener Question: Early Cancer DetectionDaniel Kim asks about pre-cancer detection and its potential impact.(00:24:44) Liquid Biopsy in ImmunotherapyUsing liquid biopsy to track and improve immune-based treatments.(00:27:35) Monitoring CAR T-Cell TherapyHow liquid biopsy helps assess immune cell expansion.(00:32:02) EPIC-Seq: Inferring RNA from DNAUsing DNA fragmentation to predict gene expression in tumors.(00:34:49) Targeting Tumor Support SystemsTreatment strategies disrupting the tumor microenvironment.(00:35:52) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook

What if you could take control of your health and add years to your life? In this episode of Next Steps 4 Seniors: Conversations on Aging, Wendy Jones sits down with Dr. John Calado to uncover the secrets to longevity, early detection, and proactive health measures that can make all the difference.

Join us as we review recent articles and news featured in The DIGEST issues #59-61, including cfDNA and incidental detection of cancer in pregnancy, vitamin K2 for nocturnal leg cramps, the danger of as-needed anti-hypertensive medications in the hospital, GLP-1 agonists for alcohol use disorder, short-course (7 vs 14 days) antibiotics for bacteremia, and patient-collected HPV testing for cervical cancer screening. Fill your brain hole with a fully digestible meal! Featuring Laura Glick MD, Nora Taranto (@norataranto), Paul Williams (@paulnwilliamz), and Matt Watto (@doctorwatto).  Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments 00:00 Introduction and Overview 02:57 The IDENTIFY study: Non-Invasive Prenatal Testing and Cancer Detection with cfDNA 05:54 Implications of Non-Reportable Results in Prenatal Testing 08:51 Vitamin K2: A New Approach to Managing Nocturnal Leg Cramps 12:07 Practicality and Future of Vitamin K2 in Clinical Practice 23:21 The Dangers of As-Needed Antihypertensives in the hospital 32:21 Exploring GLP-1 Agonists for Alcohol Use Disorder 40:24 Shorter Antibiotic Courses in Sepsis 46:09 Advancements in Patient-Collected HPV Screening for cervical cancer Credits Written and Produced by: Nora Taranto MD, Laura Glick MD, Matthew Watto MD, FACP; Paul Williams MD, FACP Show Notes: Nora Taranto MD Cover Art: Matthew Watto MD, FACP Hosts: Nora Taranto MD, Laura Glick MD, Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Emi Okamoto MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Disclosures The Curbsiders report no relevant financial disclosures.  Sponsor: Bombas Head over to Bombas.com/curb and use code curb for 20% off your first purchase. Sponsor: Pretty Litter  Go to PrettyLitter.com/curb to save twenty percent on your FIRST order and get a free cat toy.  Sponsor: Rocket Money  Cancel your unwanted subscriptions and reach your financial goals faster with Rocket Money. Go to RocketMoney.com/CURB today.

Dr. Raz joins Dorothy Gibbons to discuss the increasing incidence of breast cancer in women under 40 and the challenges of early detection. He explains that improved screening technology and methodologies are revealing more cases and emphasizes the need for nuanced risk stratification models to identify higher-risk women earlier. Key Questions Answered 1. Has cancer increased in younger women? 2. What does incidence refer to? 3. Why might the incidence of cancer be increasing? 4. Would changing the screening age for cancer be beneficial? 5. How could screening methodologies be improved? 6. Why is it challenging to determine an appropriate screening age? 7. How does race and socioeconomic status affect cancer detection and outcomes? 8. What tools or models can help in risk stratification for breast cancer? 9. Why is a consensus from national bodies necessary for changing screening guidelines? 10. What advancements in breast cancer screening are promising? Timestamped Overview 00:00 Rising Cancer Detection Rates 03:23 Rising Breast Cancer Risks in Women 09:26 MRI Advancements and Cancer Detection 12:41 Ultrasound Enhances Cancer Detection 14:25 Distinct Cancer Pathology in Screenings 16:26 Peripartum Cancer Detection Challenges Subscribe to Let’s Talk About Your Breasts on Apple Podcasts, Spotify, iHeart, and wherever you get your podcasts.See omnystudio.com/listener for privacy information.

In this episode, Dr. Shawn Tassone discusses various aspects of hormone health, particularly focusing on breast cancer screening methods including mammography, ultrasound, and thermography. He shares insights from his book, 'The Hormone Balance Bible', and emphasizes the importance of understanding different testing methods, their pros and cons, and emerging technologies in breast imaging. The conversation aims to empower women with knowledge about their health and the options available for cancer detection and prevention. Episode Highlights: The Hormone Balance Bible provides insights into hormone imbalances. Mammography, ultrasound, and thermography are key breast cancer screening methods. Each screening method has its own pros and cons. Thermography is a physiological test, while mammography and ultrasound are structural tests. Mammograms can miss fast-growing tumors due to their nature. Ultrasound can detect some tumors missed by mammograms. Thermography has a lower false positive rate compared to mammograms and ultrasounds. Emerging technologies like the QT scan may offer new options for breast imaging. Prevention is more important than detection in cancer care. Women should choose the screening method that resonates with them.  

As cancer rates in the West, and globally, tack upwards due to lifestyle and environmental pollution, so does the need for the nuclear isotopes used in detecting those cancers in a medical setting. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Louie Helmecki shares his deeply personal journey through multiple cancer diagnoses, shedding light on the emotional, physical, and medical challenges he faced along the way. From enduring chemotherapy and surgeries to navigating the complexities of cancer recurrence, Louie speaks candidly about the toll of treatment and the resilience required to push forward. He and Freddie Kimmel discuss the critical role of health ownership, the importance of advocating for the right medical care, and the gaps in traditional medicine that often leave patients searching for more holistic solutions. Louie's story is not just about surviving but about reclaiming control over his well-being and redefining what it means to thrive beyond cancer. This conversation also delves into groundbreaking health innovations, including the use of peptides, GLP-1 medications, and lifestyle medicine as tools for recovery and disease prevention. Freddie and Louie explore the latest advancements in cancer detection, weight management, and muscle preservation, emphasizing the importance of a personalized and proactive approach to health. They highlight the growing integration of complementary therapies like red light therapy, IV treatments, and biohacking strategies that support the body's natural healing process. More than just a story of struggle, this episode is a testament to the power of mindset, education, and taking action to build a life beyond illness.Chapters00:00 Introduction to Cancer Journeys05:00 Louie's Cancer Diagnosis and Initial Treatment09:52 Chemotherapy Experiences and Challenges16:01 Surgery and Recovery Insights20:01 Recurrence and New Diagnosis30:00 Navigating Medical Decisions and Expert Opinions35:50 Navigating Cancer Treatment Experiences41:07 The Intersection of Traditional and Complementary Medicine49:01 Innovations in Health and Wellness Practices55:46 Understanding Peptides and Their Impact on Health01:05:59 Exploring Weight Loss Medications01:08:02 The Importance of Comprehensive Health Assessments01:09:55 Navigating Weight Loss Programs Responsibly01:12:03 Innovative Approaches to Health and Wellness01:16:52 Cancer Detection and Preventative Measures01:26:51 Life Lessons from Cancer SurvivalUPGRADE YOUR WELLNESSSilver Biotics Wound Healing Gel: https://bit.ly/3JnxyDD (30% off)Code: BEAUTIFULLYBROKENSaga Bands: https://ca.saga.fitness/?ref=titvyccmCode: beautifullybrokenStemRegen: https://www.stemregen.co/products/stemregen?_ef_transaction_id=&oid=1&affid=52Code: beautifullybrokenLightPathLED https://lightpathled.pxf.io/c/3438432/2059835/25794Code: beautifullybroken CONNECT WITH FREDDIE Check out my website and store: (http://www.beautifullybroken.world) Instagram: (https://www.instagram.com/beautifullybroken.world/) YouTube: (https://www.youtube.com/@BeautifullyBrokenWorld)

Today I'm speaking with Dr. Paziotopoulos on the Longevity Optimization Podcast. In this episode, we explore his unique journey into the field of medicine and longevity, focusing on the integration of AI in health monitoring and the innovative concept of medical maintenance engineering. The conversation delves into the importance of imaging, the role of supplements, and the critical significance of compliance in health programs. Dr. Paziotopoulos highlights key compounds for longevity, emphasizing the essential role of vitamin D in overall health and its importance in cancer prevention. Dr. Paziotopoulos is a distinguished physician and researcher with a deep commitment to advancing the field of longevity and personalized medicine. With a background in both traditional medicine and cutting-edge technology, he has become a thought leader in the integration of artificial intelligence into health monitoring systems. His expertise encompasses a wide range of health topics, including the development of innovative health protocols and the exploration of novel compounds that promote longevity. Dr. Paziotopoulos is particularly passionate about the role of vitamin D in health, as well as the importance of water filtration and gut health. His forward-thinking approach emphasizes the need for data-driven solutions in healthcare, making him a pivotal figure in the future of age-reversal medicine and functional health. Follow him on Instagram : https://www.instagram.com/alexpazio/ Timestamps 02:57 The Journey to Medicine and Longevity 06:11 Medical Maintenance Engineering: A New Approach 09:05 Imaging and AI in Health Monitoring 11:59 The Role of Supplements in Longevity 18:03 The Importance of Compliance in Health Programs 21:01 Exploring Key Compounds for Longevity 23:59 The Benefits of Natural Foods vs. Supplements 26:57 Vitamin D: The Essential Hormone for Health 31:04 Vitamin D and Cancer Prevention 32:41 Exploring Methylene Blue 34:32 The Importance of Water Filtration 40:53 Patient Management and Protocol Development 52:33 Age-Reversal Medicine and Future Therapies 01:01:04 The Future of Medical Maintenance Engineering 01:03:43 The Future of Data-Driven Medicine 01:12:27 Understanding Omics and Personalized Health 01:19:24 AI's Role in Longevity and Health Optimization 01:26:40 Innovations in Cancer Detection and Treatment

Dr. Lecia Sequist, an expert in lung cancer and early detection, and Dr. Jeff Yang, a renowned thoracic surgeon, join Chadi to unravel the complexities of early lung cancer detection. Together, they explore the nuances of lung cancer screening, including the challenges of overdiagnosis and managing false-negative and false-positive results. The discussion delves into cutting-edge advancements like multi-cancer early detection tests, current patient screening eligibility criteria, and the critical factors contributing to low screening rates, such as accessibility barriers. They end on a note to raise awareness about the importance of lung cancer screening, emphasizing its safety, simplicity, and potential to save lives. Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Dr. Sunil Pai reveals three crucial health tests that most doctors overlook. Learn how these tests can provide vital insights into your health and empower you to take control of your well-being. Discover the tools to optimize your health today! #HealthTests #EmpowerYourHealth #Wellness

AI Weekly Rundown January 05th to January 12th 2025:

In today's episode, I reveal the top health trends of 2025 that you can't afford to miss.   What We Discuss: 2025 Trends in Health ... 01:15 GLP1s: Managing body composition with emerging variations ... 01:30 Importance of lifestyle factors such as diet and exercise alongside GLP1s ... 03:45 Home Testing Innovations ... 05:05 Theriom's Aristotle Test and upcoming microbiome test ... 05:25 MI Screen: Non-invasive mitochondrial function test ... 07:40 True Diagnostic: The Harmony Test for aging ... 09:00 Syphox: Comprehensive blood analysis innovation ... 10:45 Vaitrakt: Affordable gut microbiome test ... 11:35 Prodrome Science Test: Practitioner guided health insights ... 13:20 Early Cancer Detection Advances ... 15:00 Auria Test: Tear-based breast cancer detection ... 16:50 QT Scan: Imaging dense breasts non-invasively ... 18:35 Cardiovision Care: Predictive cardiovascular disease test ... 20:10 Emerging Technologies in Peptides and Bioregulators ... 21:45 Enhanced bioavailability through skin delivery ... 22:00 Addressing past traumas and experiences for holistic health ... 27:25 Closing Remarks and Teasers for Future Episodes ... 31:30     Made Possible By Our Amazing Sponsor: Mitopure from Timeline: Improve your cellular health by taking Mitopure in its simplest form with two vegan softgels daily for the recommended dose of Urolithin A (500mg of Mitopure). Visit timeline.com/nat10 for 10% off. That's timeline.com/nat10.     Nat's Links: YouTube Channel Join My Membership Community Sign up for My Newsletter  Instagram  Facebook Group  

Part 4 of 4: My guest today is Cyriac Roeding, founder, investor, and CEO of Earli, a company on a mission to transform cancer into a manageable condition. Using innovative gene therapy approaches, Earli's technology forces cancer cells to produce a synthetic, non-human biomarker—overcoming the limitations of relying on naturally occurring biomarkers that cancer may or may not provide.

A Daily Chronicle of AI Innovations on January 08th 2025 ⚡Nvidia CEO Says His AI Chips Are Improving Faster Than Moore's Law

Artificial intelligence-enabled medical diagnostic tools are ensuring greater accuracy in cancer screening and detection, helping doctors arrive at more precise diagnoses and enhancing treatment quality.Zhejiang University recently introduced an AI-powered universal pathology assistant called OmniPT, which integrates vision and language models for human-computer interaction. The model is being used at the First Affiliated Hospital of Zhejiang University School of Medicine's department of pathology, focusing on high-incidence cancers such as gastric, colorectal and cervical. The hospital in Hangzhou, the capital of Zhejiang province, is the first clinical institution in China to use an AI-powered pathology assistant.OmniPT has achieved a number of breakthroughs in laboratory tests, including in cancer classification, grading, vascular and neural invasion identification and the discovery of markers that indicate the future course of the disease, the hospital said. Analyses and predictions by OmniPT have been 80 to 90 percent accurate across cancer types.Most patients and their families are unfamiliar with the details of pathology examinations — work performed on tissue samples or cells in a lab, and pathologists generally do not interact directly with patients.When biological samples from a patient are sent to a lab, experts go through an intense process to understand the pathological changes and the nature of the disease in the specimen at hand.The role of the pathologist is to help reach an accurate diagnosis through the application of rigorous empirical standards. China, however, faces a severe shortage of pathology professionals."Many people may know that pediatricians are in short supply, but pathologists are even more rare. Currently, our country needs 150,000 to 200,000 pathologists, but there are only about 30,000 officially registered," said Zhang Jing, chair of the pathology department and vice-president of the Yuhang branch of the hospital.Apart from this massive gap, there are also regional imbalances. While cities like Beijing, Shanghai and Hangzhou may be facing less severe shortages, the situation is dire in remote areas, he added.Additionally, the long training period only complicates the situation as young pathologists often lack the required depth of experience.Against this backdrop, OmniPT, developed by Professor Song Mingli's team from Zhejiang University's College of Computer Science and Technology in collaboration with the First Affiliated Hospital, is facilitating fast, accurate clinical diagnosis.By leveraging human-computer interaction and centering on the needs of pathologists, OmniPT significantly improves diagnostic efficiency and quality, and helps alleviate the shortage of professionals."It serves as an assistant to pathologists by handling repetitive tasks so that they can focus on final judgment," Zhang said.He provided an example of counting mitosis, which is a critical task when diagnosing gliomas, a kind of tumor that can be found in the brain or spinal cord."It can take at least 30 minutes to an hour to count a single pathology slide under a high-power microscope," he said."OmniPT, however, can complete this task in less than 10 seconds. Its computational capabilities allow it to analyze the findings in far greater detail than manual work. When it encounters 10 uncertain mitotic figures, it reports to a pathologist like me to make the final judgment," Zhang added.In collaboration with the hospital, Song's team has focused on clinical needs. OmniPT accelerates the evaluation of samples on slides, particularly details that might be overlooked by fatigued doctors. OmniPT handles more than 90 percent of repetitive tasks, leaving only a small fraction for pathologists to assess."It assists us, but it doesn't drive us. We drive it. By leveraging AI in our interactions, we can solve challenging problems in pathology — particularly for people in remote regions or those with less experienced doctors. It greatly improves efficiency, reduces costs and helps us avoid errors," Zhang said.

Powered by Peerr   In this week's episode Neil shares his journey from consulting into building Skin Analytics, the only UKCA approved Class IIa AI as a Medical Device for dermatology with an 99.8% accuracy of ruling out of skin cancer!     We discussed:

Happy Thanksgiving!I'm not a financial advisor; Superpowers for Good should not be considered investment advice. Seek counsel before making investment decisions.Watch the show on television by downloading the e360tv channel app to your Roku, AppleTV or AmazonFireTV. You can also see it on YouTube.When you purchase an item, launch a campaign or create an investment account after clicking a link here, we may earn a fee. Engage to support our work.Devin: What is your superpower?Jonathan: I think in my case, if I may, some of my strengths include being a very creative CEO.Making life-saving cancer detection accessible to everyone, regardless of income, is the driving force behind Jonathan Cohen's leadership at 20/20 GeneSystems. On today's episode of Superpowers for Good, Jonathan shared how his team is reshaping cancer testing and leveraging equity crowdfunding to align with their mission.The company's flagship product, OneTest, offers multi-cancer early detection for as little as $200—far below the cost of competing tests. Recently, they introduced a convenient home collection option, allowing people to collect samples themselves, bypassing painful and time-consuming traditional blood draws. “We believe that cancer testing should not just be for the so-called worried rich. It should be for everybody,” Jonathan said.This philosophy extends to their approach to financing. Jonathan explained, “Just as cancer doesn't discriminate by income, we think cancer testing—and the opportunity to invest in innovations—should be available to all.” The company pioneered equity crowdfunding for biotech, raising $12 million from nearly 8,000 shareholders through Reg CF and Reg A campaigns. Now, they are hosting another offering on WeFunder to continue this democratized model.Jonathan's vision is deeply personal for many. He highlighted how shareholders often become customers and vice versa, strengthening the connection between the company's mission and its community.By focusing on affordability, accessibility, and inclusivity, 20/20 GeneSystems is setting a new standard—not just for cancer detection but also for how groundbreaking medical innovations are funded. Their journey illustrates the powerful impact of aligning purpose with action, offering investors and patients alike a chance to join a life-saving mission.tl;dr:* Jonathan Cohen's company offers one of only two multi-cancer early detection tests available today.* 20/20 GeneSystems' OneTest uses protein biomarkers, providing an affordable alternative to DNA-based diagnostics.* The company's equity crowdfunding campaigns align with its mission of democratizing access to biotech investments.* During the COVID-19 pandemic, 20/20 GeneSystems pivoted quickly to become an early leader in testing.* Jonathan's innovative approach integrates AI and machine learning, modernizing cancer detection and expanding accessibility.How to Develop Creative Thinking As a SuperpowerJonathan Cohen's superpower is creative thinking. As the CEO of 20/20 GeneSystems, Jonathan has repeatedly demonstrated an ability to think outside the box to solve problems and innovate. From spearheading novel approaches to cancer detection to adopting unconventional business strategies, Jonathan's creativity enables him to navigate complex challenges and seize unique opportunities.During the early days of the COVID-19 pandemic, Jonathan's creativity shone when he led 20/20 GeneSystems to pivot quickly into COVID testing. With rapid antibody tests sourced from East Asia, the company was among the first in the U.S. to offer any type of COVID test. Later, they transitioned to PCR testing, adapting to market needs. This quick, strategic shift not only supported public health efforts but also drove substantial growth, earning the company a spot on the Inc. 5000 list of fastest-growing companies.Tips for Developing Creative Thinking:* Pause and Analyze: Avoid following the crowd; take time to assess alternative approaches when everyone else moves in a single direction.* Leverage Technology: Use emerging tools like AI and machine learning to modernize older, proven methods.* Think Holistically: Combine diverse strategies, such as integrating different testing modalities for optimal outcomes, as Jonathan did with protein and DNA testing.* Engage in Public Policy: Collaborate with policymakers to align innovative solutionsBy following Jonathan Cohen's example and advice, you can make creative thinking a skill. With practice and effort, you could make it a superpower that enables you to do more good in the world.Remember, however, that research into success suggests that building on your own superpowers is more important than creating new ones or overcoming weaknesses. You do you!Guest ProfileJonathan Cohen (he/him):President & CEO, 20/20 GeneSystemsAbout 20/20 GeneSystems: We develop and commercialize innovative lab tests for the early detection and prevention of cancers and chronic conditions.Website: www.OneTestforCancer.comOther URL: wefunder.com/2020.gene.systemsBiographical Information: Jonathan Cohen is a visionary life sciences entrepreneur and executive with extensive experience in the biotechnology and healthcare industries. Throughout his career, Jonathan has succeeded at the intersection of capital formation, start-ups and public policy. As the founding CEO of 20/20 GeneSystems, Inc., he has pioneered groundbreaking initiatives in innovative lab testing for the early detection and prevention of cancers and other diseases. These include co-invention of blood tests w/AI-powered algorithms for the early detection of multiple cancers and chronic inflammation. Jonathan is a longtime advocate for state and federal policies that advance the entrepreneurial life sciences industry.Linkedin: linkedin.com/in/jonathan-cohen-22574a12/Support Our SponsorsOur generous sponsors make our work possible, serving impact investors, social entrepreneurs, community builders and diverse founders. Today's advertisers include FundingHope, Inner Space KC, Honeycomb Credit and How to Make Money with Impact Crowdfunding. Learn more about advertising with us here.Max-Impact MembersThe following Max-Impact Members provide valuable financial support to keep us operating:Carol Fineagan, Independent Consultant | Lory Moore, Lory Moore Law | Marcia Brinton, High Desert Gear | Paul Lovejoy, Stakeholder Enterprise | Ralf Mandt, Next Pitch | Add Your Name HereUpcoming SuperCrowd Event CalendarIf a location is not noted, the events below are virtual.* SuperCrowdHour, December 18, 2024, at 1:00 PM Eastern. Each month, we host a value-laden webinar for aspiring impact investors or social entrepreneurs. At November's SuperCrowdHour, Jason Fishman of Digital Niche Agency will share insights. Free to attend.* Impact Cherub Club Meeting hosted by The Super Crowd, Inc., a public benefit corporation, on December 17, 2024, at 1:00 PM Eastern. Each month, the Club meets to review new offerings for investment consideration and to conduct due diligence on previously screened deals. To join the Impact Cherub Club, become an Impact Member of the SuperCrowd.Community Event Calendar* Successful Funding with Karl Dakin, Tuesdays at 10:00 AM ET - Click on Events* Community Revitalization, Thursdays, 10:00 AM Eastern.* CfPA Webinar with President-Elect Jenny Kassan sharing her vision for 2025, December 11 at 2:00 PM Eastern.* NC3 Changing the Paradigm: Mobilizing Community Investment Funds, March 7, 2025* Asheville Neighborhood Economics, date TBD following impact of Helene.If you would like to submit an event for us to share with the 8,000+ members of the SuperCrowd, click here.We use AI to help us write compelling recaps of each episode. Get full access to Superpowers for Good at www.superpowers4good.com/subscribe

“Our mission is to make cancer less deadly through widely accessible next-generation early-detection blood tests.” Susan Tousi, CEO of Delfi Diagnostics, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Tousi joins BI analyst Jonathan Palmer to discuss the company's fragment-based liquid biopsy technology and the immense opportunity to save lives through early cancer detection. Starting with lung cancer via its FirstLook test, Delfi expects to expand more broadly into other cancer types and applications like monitoring with a focus on access and affordability. The conversation touches on the company's core values and the large opportunity set afforded by recent funding rounds.See omnystudio.com/listener for privacy information.

BUFFALO, NY - November 11, 2024 – A new #editorial was #published in Oncotarget's Volume 15 on November 7, 2024, titled “Beyond the hype: Navigating bias in AI-driven cancer detection.” In this editorial, researchers from the Mayo Clinic emphasize the need to address potential biases in Artificial Intelligence (AI) tools used for cancer detection to ensure fair and equitable healthcare. Authors Yashbir Singh, Heenaben Patel, Diana V. Vera-Garcia, Quincy A. Hathaway, Deepa Sarkar, and Emilio Quaia discuss the risks of biased AI systems, which can lead to disparities in diagnosis and treatment outcomes across diverse patient groups. While AI is transforming cancer care through early diagnosis and improved treatment planning, this study warns that AI models trained on limited or non-diverse data may misdiagnose or overlook certain populations, particularly those in underserved communities, thereby increasing healthcare disparities. As explained in the editorial, “For example, if an AI model is trained on Caucasian patients, it may struggle to detect skin cancer accurately in patients with darker skin, leading to missed diagnoses or false positives.” Such biases could result in unequal access to early diagnosis and treatment, ultimately leading to poorer health outcomes for certain groups. Beyond racial bias, factors such as socioeconomic status, gender, age, and geographic location can also affect the accuracy of AI in healthcare. The authors propose a comprehensive approach to developing fair AI models in healthcare, highlighting six key strategies. They first emphasize the importance of using diverse and representative datasets to improve diagnostic accuracy across all demographics. Rigorous testing and validation across various population groups are necessary before AI systems are widely implemented. To promote ethical AI use, models should be transparent in their decision-making processes, enabling clinicians to recognize and address potential biases. The researchers also advocate for collaborative development involving data scientists, clinicians, ethicists, and patient advocates to capture a range of perspectives. Continuous monitoring and regular audits are essential to detect and correct biases over time. Finally, training healthcare providers on AI's strengths and limitations will empower them to use these tools responsibly and make informed interpretations. “The goal should not merely be to create AI systems that are more accurate than humans but to develop technologies that are fundamentally fair and beneficial to all patients.” The authors also urge regulatory bodies, such as the U.S. Food and Drug Administration (FDA), to implement updated frameworks specifically aimed at addressing AI bias in healthcare. Policies that promote diversity in clinical trials and incentivize the development of fair AI systems will help ensure that AI benefits reach all populations equitably. They caution against over-reliance on AI without a full understanding of its limitations, as unchecked biases could undermine patient trust and slow the adoption of valuable AI technologies. In conclusion, as AI continues to transform cancer care, the healthcare sector must prioritize fairness, transparency, and robust AI regulation to ensure that it serves all patients without bias. By addressing bias from development through to implementation, AI can fulfill its promise of creating a fair and effective healthcare system for everyone. DOI - https://doi.org/10.18632/oncotarget.28665 Correspondence to - Yashbir Singh - singh.yashbir@mayo.edu To learn more about Oncotarget, please visit https://www.oncotarget.com. MEDIA@IMPACTJOURNALS.COM

Today on Beating Cancer Daily, Saranne brings a lighthearted and informative perspective to cancer detection. After a listener praises her for making cancer more approachable, Saranne realizes the impact humor can have in the fight against this illness. She recounts her own journey with Stage IV breast cancer and emphasizes the importance of regular cancer screenings, especially for skin cancer. Infusing humor into serious topics, she utilizes a Dr. Seuss-inspired rhyme to remember critical signs of skin anomalies and introduces the ABCDEF mnemonic from the Princeton Longevity Center as a practical self-checking method. "Catchy rhymes can save lives; check for brownish spots, dark black dots, and odd-shaped moles." ~ Saranne Today on Beating Cancer Daily: ·     Emphasize the importance of regular skin checks for early detection of cancer·     Use humor to make self-checking for skin cancer more approachable·     Explain a helpful mnemonic (ABCDEF) for remembering key signs of skin anomalies·     Share personal experience to illustrate that even those focused on one type of cancer should remain vigilant about others·     Encourage taking photos of any suspicious skin changes for comparison over time·     Highlight the importance of knowing your family history related to skin cancer·     Recommend consulting with healthcare providers when any changes are noticed·     Remind listeners to help each other with skin checks, especially in hard-to-see areas Resources Mentioned: Princeton Longevity Centerhttps://princetonlongevitycenter.com/ EWG Sunscreen Guidehttps://www.ewg.org/sunscreen/ The #1 Rated Cancer Survivor Podcast by FeedSpot and Ranked the Top 5 Best Cancer Podcast by CancerCare News, Beating Cancer Daily is listened to in more than 91 countries on six continents and has over 300 original daily episodes hosted by stage IV survivor Saranne Rothberg!   To learn more about Host Saranne Rothberg and The ComedyCures Foundation:https://www.comedycures.org/ To write to Saranne or a guest:https://www.comedycures.org/contact-8 To record a message to Saranne or a guest:https://www.speakpipe.com/BCD_Comments_Suggestions To sign up for the free Health Builder Series live on Zoom with Saranne and Jacqui, go to The ComedyCures Foundation's homepage:https://www.comedycures.org/ Please support the creation of more original episodes of Beating Cancer Daily and other free ComedyCures Foundation programs with a tax-deductible contribution:http://bit.ly/ComedyCuresDonate THANK YOU! Please tell a friend who we may help, and please support us with a beautiful review. Have a blessed day! Saranne

In this episode of the Gladden Longevity Podcast, Dr. Jeffrey Gladden and Steve Reiter discuss various aspects of health optimization, focusing on longevity, pregnancy health, and breast cancer awareness. They explore innovative therapies like ozone treatment and detoxification methods, as well as provide actionable recommendations for couples planning for pregnancy. The conversation also addresses common myths surrounding breast cancer, emphasizing the importance of genetics and regular screenings. In this episode, the conversation delves into various aspects of cancer detection, treatment, and overall health maintenance. The discussion highlights the importance of understanding cancer testing methods, the reality of remission, and innovative therapies that support the immune system. Additionally, the episode emphasizes the significance of lung health through exercise and the critical role of dental hygiene in overall health. The conversation concludes with exciting developments in rejuvenation procedures that promise significant health benefits.   For the audience ·      Use code 'Podcast10' to get 10% OFF on any of our supplements at https://gladdenlongevityshop.com/ !    Takeaways   ·      The mitochondria play a crucial role in energy production and immune response. ·      Ozone therapy can rejuvenate mitochondrial function and aid in detoxification. ·      Frequent sexual activity can improve reproductive health for men. ·      Inositol can help women with PCOS improve their chances of pregnancy. ·      Adequate iodine levels can significantly impact a baby's IQ. ·      Regular exercise is beneficial for both pregnancy and overall health. ·      Avoiding heat exposure is important for male fertility. ·      Genetic testing can provide insights into breast cancer risk. ·      Mammograms are not the only screening method for breast cancer. ·      Circulating tumor cell tests can detect cancer earlier than traditional methods.  ·      Circulating tumor cells are crucial for cancer detection. ·      Remission does not mean the absence of cancer. ·      Innovative therapies can enhance immune response against cancer. ·      Exercise is vital for maintaining lung health. ·      Dental hygiene impacts systemic health significantly. ·      Root canals may lead to latent infections affecting health. ·      Regular exercise improves outcomes for cancer patients. ·      Breathing techniques can enhance lung function during exercise. ·      New rejuvenation procedures show promising results for recovery. ·      Understanding oral bacteria is essential for overall health.   Chapters   00:00 Introduction to Age Hacking and Longevity 10:01 Health Recommendations for Pregnancy: Answering a Listener's Q 21:44 Breast Cancer Awareness and Myths 26:09 Understanding Cancer Detection and Testing 28:50 The Reality of Cancer Remission 30:43 Innovative Cancer Therapies and Immune System Support 35:02 Enhancing Lung Health Through Exercise 43:00 The Importance of Dental Hygiene 48:43 Exciting Developments in Rejuvenation Procedures   Articles, News and Supplements mentioned Breast Cancer BREAST CANCER MYTHS https://www.wkrn.com/news/tennessee-news/breast-cancer-awareness-month-common-myths-about-the-disease/   BREAST CANCER GUIDE EVERYONE SHOULD HAVE https://www.telegraph.co.uk/health-fitness/conditions/cancer/breast-cancer/   NEW TECH FOR CANCER SCREENING https://www.cbsnews.com/chicago/news/doctor-talks-new-technology-importance-of-breast-cancer-screenings/   NEW WAY TO KILL CANCER CELLS https://medicalxpress.com/news/2024-10-cancer-cells-longer-people-breast.html   Healthy Lungs BENEFITS OF EXERCISE FOR PATIENTS WITH LUNG CANCER https://medicalxpress.com/news/2024-10-people-lung-cancer-grueling-evidence.html   HABITS PULMONOLOGISTS ARE BEGGING PEOPLE TO ADOPT AND DITCH https://parade.com/health/the-one-habit-to-adopt-asap-if-you-have-severe-asthma-according-to-pulmonologists   Dental Hygiene DENTAL HEALTH SENSING WITH SONIC TOOTHBRUSH https://medicalxpress.com/news/2024-10-exploring-dental-health-sonic-toothbrush.html   DENTAL HYGIENIST TALKS ABOUT HOW TO SPOT PERIODONTAL DISEASE https://www.buzzfeed.com/meganeliscomb/smell-your-used-floss-tiktok   UGLY YET MOST HIGHLY EFFECTIVE TOOTHBRUSH REVIEWERS HAVE EVER USED https://www.huffpost.com/entry/flossing-toothbrush_l_66fefb0de4b089d324aa50b1/amp   Supplements MOLECULAR HYDROGEN – ENERGY https://gladdenlongevityshop.com/products/h2-molecular-hydrogen-30-ct   MOLECULAR HYDROGEN – CHILL https://gladdenlongevityshop.com/products/h2-molecular-hydrogen-product-h2-chill   TOOTH AND GUM ESSENTIALS TOOTH PASTE https://gladdenlongevityshop.com/products/tooth-gum-essentials-toothpaste-4oz-1?_pos=1&_psq=dental&_ss=e&_v=1.0   TOOTH AND GUM TONICS https://gladdenlongevityshop.com/products/tooth-gum-tonic-18-fl-oz-1?_pos=2&_psq=dental&_ss=e&_v=1.0    UPGRADED IODINE https://gladdenlongevityshop.com/products/upgraded-memory-4fl-oz?pr_prod_strat=e5_desc&pr_rec_id=ec1b1eb28&pr_rec_pid=8125057761519&pr_ref_pid=8125058580719&pr_seq=uniform    ZINC https://gladdenlongevityshop.com/products/zinc-glycinate-120-gels-1?_pos=1&_psq=zinc&_ss=e&_v=1.0    Send your Qs for future episodes! Email: podcast@gladdenlongevity.com   Reach out to us at: Website: https://gladdenlongevity.com/  Facebook: https://www.facebook.com/Gladdenlongevity/ Instagram: https://www.instagram.com/gladdenlongevity/?hl=en  LinkedIn: https://www.linkedin.com/company/gladdenlongevity YouTube: https://www.youtube.com/channel/UC5_q8nexY4K5ilgFnKm7naw 

The Smart 7 is an award winning daily podcast that gives you everything you need to know in 7 minutes, at 7am, 7 days a week...With over 16 million downloads and consistently charting, including as No. 1 News Podcast on Spotify, we're a trusted source for people every day and the Sunday 7 won a Gold Award as “Best Conversation Starter” in the International Signal Podcast Awards If you're enjoying it, please follow, share, or even post a review, it all helps...Today's episode includes the following guests:Guests Chiara De Blaise - Director of Health Services at Prostate Cancer UkAmy Rylance - Assistant Director of Health Improvement at Prostate Cancer UkWill Guyatt - The Smart 7's Tech Guru Oliver Madden - Enterprise Browser Specialist at Google's Chrome Bas Burger - CEO of BT Business ServicesJess Figueras - Chief Executive of Pionen Security and Acting Chair of Trustees at the Uk Cyber Council Andre Riveros - Associate Professor at Rosario University in Bogota, Colombia Juan Jose Uvalle is a Natural Science Student at Rosario University in Bogota, ColombiaAntonio Guterres - UN Secretary General Hector Ganan Bueno - Member of the National Indigenous Guard of Colombia Matthew Gould is the Chief Executive of the Zoological Society of LondonRichard Evans -CEO of the Society of Radiographers Marc Warner - CEO of Faculty AIBaroness Shami Chakrabarti - Former Director of Civil Rights Advocacy group Liberty and Labour MPSara Marchant - Vets Practice Manager at Kirks Vets in South LincolnshireContact us over at X or visit www.thesmart7.comPresented by Ciara Revins, written by Liam Thompson and produced by Daft Doris. Hosted on Acast. See acast.com/privacy for more information.

Cancer left undetected can swiftly evolve from a silent threat to a devastating diagnosis. But what if cancer could be detected and treated at its inception? Sumit Rai, CEO of Cancer Check Labs, is on a mission to dramatically increase survival rates.  In this week's episode, sponsored by Physician Growth Accelerator, Sumit shares a compelling narrative that highlights both his personal journey into cancer detection technology and the revolutionary capabilities of his company's new cancer screening test. After losing his sister to cancer shortly after his exit from a successful venture in mobile advertising, Rai channeled his grief into a fervent quest to transform cancer diagnostics. His story is not just about loss but about leveraging technology to pioneer early cancer detection methods that boast a staggering potential to change survival outcomes. What we discuss in the episode: The science behind the test, which processes an unprecedented volume of blood to detect CTCs How Cancer Check Labs' approach differs from liquid biopsies The opportunity for a new era of proactive healthcare Bridging the gap between current medical practice and cutting-edge technology How integrating comprehensive diagnostic technologies could drastically reduce cancer mortality and reshape the landscape of cancer care Resources from this episode:  Get the free MedTech Talk Tracks for Action Physician Growth Accelerator Cancer Check Labs Social Media: Connect with Sumit on LinkedIn Connect with Zed on LinkedIn Connect with Clark on LinkedIn

The Yale Cancer Center was just awarded a grant to utilize artificial intelligence to find older women with low-risk breast cancer who might be candidates for active surveillance rather than immediate treatment. We got a better understanding of the work being done to avoid overtreatment for some cancer patients from Dr. Sanjay Aneja, physician scientist and researcher at Yale Cancer Center. For more information: https://medicine.yale.edu/news-article/yale-cancer-center-team-receives-yosemiteamerican-cancer-society-award/ Image Credit: Getty Images 

Recent research from the University of Chicago shows that only 14% of cancers in the U.S. are diagnosed after the patient had a recommended screening test. 57% of diagnosed cancers do not have screening tests and account for 70% of all cancer-related deaths. 86% of cancer cases still go undiagnosed after recommended screenings. ‍16M+ life years saved in the U.S. from early-detection screenings. I don't know about you, but everytime I read those stats, my jaw hits the floor.When it comes to cancer, early detection is key to saving lives. With 610,000+ cancer deaths in the U.S. each year, most of which stemming from cancer types with no FDA-approved screening options, new technology is making revolutionary strides in detecting cancers that have been previously undetectable in early stages.There are now new tools intended to be used complementary to established cancer screening assessments. However in some cases, especially for cancer types that have no previously established screening test and are notoriously hard to detect, it may be the only warning sign currently available for providers.In this week's episode of the Everything Epigenetics podcast, Dr. Joshua Routh and I talk about just that. We discuss the rising cancer burden and the cutting-edge role epigenetics plays in revolutionizing early cancer detection. Dr. Routh, a molecular genetic pathologist and medical director at Precision Epigenomics, shares insights into how new diagnostics, such as Multi-Cancer Detection (MCD) tests, provide opportunities to catch cancers earlier than ever before. We also explore the technology behind these tests, their impact on patient outcomes, and what the future holds for epigenetics in diagnosing and treating cancer and other chronic diseases.You'll learn about:Dr. Joshua Routh's journey from engineering to molecular oncology.The alarming statistics behind late-stage cancer diagnoses and why early detection is critical.Current cancer screening limitations and how epigenomics offers better solutions.How Multi-Cancer Detection (MCD) tests like EPISEEK work to catch cancer earlier.The difference between EPISEEK by Precision Epigenomics and Galleri by Grail.Why test accuracy mattersWhat to expect if you get a positive cancer result and how recurrence monitoring works.The broader future of epigenetics in treating conditions like heart disease and neurological disorders.Chapters:00:10 - Introduction to Dr. Joshua Routh and His Career Journey04:48 - The Growing Cancer Burden and Challenges in Screening09:00 - How Epigenomics is Transforming Early Cancer Detection13:12 - Multi-Cancer Detection Tests: What Are They?18:22 - EPISEEK by Precision Epigenomics vs. Galleri: Comparing the Leading Tests25:27 - Cancer Therapy Resistance and the Role of EpigenetSupport the showWhere to Find Us:Instagram Twitter Facebook Follow us on:Apple Podcast Spotify YouTube Visit our website for more information and resources: everythingepigenetics.com Thank you for joining us at the Everything Epigenetics Podcast and remember you have control over your Epigenetics, so tune in next time to learn more about how to harness this knowledge for your benefit.

In today's episode, you'll get to explore the world of early cancer detection with Dr. Azra Raza, a pioneering oncologist and professor of medicine. We discuss the anxiety-inducing issues surrounding current cancer screening methods like mammograms and colonoscopies and examine advanced alternatives such as GRAIL and Cologuard. Dr. Raza also shares her groundbreaking work in detecting "The First Cell" and explores the potential of biomarkers and wearable devices for early detection (check out her fascinating book on this topic for more invaluable information!). In a deeply personal segment, Dr. Raza opens up about her late husband's battle with leukemia and how it shaped her understanding of cancer. We'll also discuss the flaws in the current cancer research model, the financial struggles for innovative scientists, and the urgent need for better funding to accelerate progress. Dr. Azra Raza is the Chan Soon-Shiong Professor of Medicine and Clinical Director of The Edward P. Evans Foundation MDS Center at Columbia University in New York. A practicing oncologist seeing 30–40 cancer patients weekly, she directs a basic cancer research lab with hundreds of original publications in high-profile journals. Her life is dedicated to the prevention of all chronic diseases, including cancer, by early detection. She worked with President Clinton, designing breakthrough developments in science and technology, and with President Joe Biden for the Cancer Moonshot initiative. Her latest book is a national bestseller and has been translated into nine languages. Dr. Raza is now involved in First Cell Therapeutics, developing a specific antibody to target and remove the tumor macrophage hybrid cells that act as The First Cell giving rise to cancer.  Full show notes: https://bengreenfieldlife.com/firstcell Episode Sponsors: Aires Tech: Aires Tech is offering you a 30% discount at airestech.com/ben by using code BEN30. Wild Health: Get 20% off with code BEN at wildhealth.com/ben. FUM: Head to tryfum.com/BEN and use code BEN to get a free gift with your Journey Pack! Vivobarefoot: You can purchase yours today with an exclusive 20% discount by going to vivobarefoot.com/bengreenfield and using code BENG20. MOSH: Head to moshlife.com/BEN to save 20% off plus FREE shipping on either the Best Sellers Trial Pack or the new Plant-Based Trial Pack.See omnystudio.com/listener for privacy information.

Dr. Neal Lonky, CEO of Histologics and an OBGYN, discusses his revolutionary tissue sampling method for cervical cancer screening. Dr. Lonky shared how his invention, the Kylon fabric, is making colposcopy procedures more compassionate and effective. The Kylon devices significantly reduce patient discomfort compared to traditional metal instruments, while providing high-quality tissue samples for pathologists. Timestamps:(00:56) Dr. Neal Lonky developed Kylon, a medical fabric for compassionate tissue sampling in colposcopy and cervical biopsies.(16:15) Studies show Kylon devices cause less pain and provide better tissue samples than traditional biopsy methods.(27:21) Kylon fabric contours to surfaces, removing and storing tissue samples that can be easily sent to labs.(36:58) Clinicians can contact Histologics for free Kylon samples, with about 60 US labs now processing these samples.(41:30) Histologics expanded Kylon technology to wound care, creating glove-like devices for gentle debridement.Host Bio:This podcast is hosted by Sheree Dibiase, PT ICLM. She is a nationally recognized women's health physical therapist who owns seven private clinics — one of the biggest networks in the US. She has spent 30+ years practicing in the oncology, pelvic floor, and prenatal postpartum healthcare spaces. She was also a professor for seven years at Loma Linda University where she taught kinesiology.Brought to you by...https://lakecitypt.com/ - Women's health physical therapy.https://pelvicfloorpro.com/ - Pelvic floor physical therapy from home.Keywords:colposcopy, cervical cancer screening, Kylon fabric, compassionate tissue sampling, biopsy. HPV testing, wound care

In this episode of the Maximal Being podcast, Dr. Erica Barnell, founder of Geneoscopy, discusses a range of topics, including the challenges and potential of Erica's technology, the importance of early detection and intervention for colorectal cancer, and her personal journey, including the persistence and determination required to navigate the FDA approval process. Topics- Colorectal Cancer Screening- Advanced Adenoma Detection and Industry Challenges - Sham or Gram: Anti-Sickness Recipe Doc Mok an advanced GI doctor specializing in nutrition, gut health, and cancer. Joining him is the podcast's layman, Jacky P, smashing the broscience on this week's podcast. Their guest Dr. Erica Barnell is the co-founder and Chief Science Officer at Geneoscopy Inc., a clinical-stage diagnostic company working on early detection of colorectal cancer. If you enjoy the podcast, would you please consider leaving a short review on Apple Podcasts/iTunes? It takes less than 60 seconds, and it really makes a differenceReach out to us at thedocmok@gmail.comOr https://www.thedocmok.com/ 5 FREE Gut Health Hacks (that your doctor won't tell you)5 Days of FREE videos delivered straight to your inbox.No obligation other than your email. I promise I won't send you constant useless garbage emails.*Plus we will send you an extra surprise*https://www.thedocmok.com/https://www.geneoscopy.com/SocialsFacebook: https://www.facebook.com/maximalbeing/Jacky P's Facebook: https://www.facebook.com/profile.php?id=100043095913342Twitter: https://twitter.com/maximalbeingInstagram: https://www.instagram.com/maximalbeings/Jacky P's Instagram: https://www.instagram.com/jackyp_cfp/Pinterest: https://www.pinterest.com/maximalbeing/Linked'in: https://www.linkedin.com/in/maximal-being-13a5051a1/YouTube: https://www.youtube.com/channel/UCi7KVUF8U-gfhOE1KSNAqIg

What is the role of blue light cystoscopy in bladder cancer? In this episode, Dr. Suzette Sutherland interviews Dr. Suzanne Merrill from Colorado Urology about the benefits of this technology in the diagnosis and treatment of bladder cancer, and how to implement it into your practice. --- CHECK OUT OUR SPONSOR Photocure https://www.photocure.com/ --- SYNPOSIS The doctors start by discussing the advantages of using blue light cystoscopy, including better detection rates of Ta and T1 lesions and the reduction of cancer recurrence by as much as 11%. They highlight the importance of complete transurethral resection of bladder tumor (TURBT) and patient compliance. Dr. Merrill emphasizes the necessity of accurate risk stratification and the logistics of real-life incorporation. Finally, she also comments on new bladder cancer technologies, such as narrow band imaging. --- TIMESTAMPS 00:00 - Introduction 03:45 - Epidemiology and Risk of Bladder Cancer 05:48 - AUA Guidelines for Bladder Cancer 08:01 - Mechanism and Benefits of Blue Light Cystoscopy 10:33 - Practical Applications 34:48 - Conclusion --- RESOURCES Photocure https://www.photocure.com/

On Passion Struck, John is joined by Michael Marquardt, former Chair of the American Cancer Society and CEO of Epi-One, to explore groundbreaking breakthroughs in early cancer detection. The two dive deep into how epigenetic signals in the DNA molecule are revolutionizing how we diagnose cancer, offering hope for earlier and more effective treatments. Don't miss this insightful conversation on the future of cancer detection!His personal experiences with cancer, including the loss of his first wife, have driven his dedication to revolutionizing cancer detection and treatment. The episode shed light on the advancements in cancer research and the critical role of early detection in improving outcomes for cancer patients.Full show notes and resources can be found here: https://passionstruck.com/michael-marquardt-breakthroughs-cancer-detection/SponsorsBabbel is the new way to learn a foreign language. The comprehensive learning system combines effective education methods with state-of-the-art technology! Right now, get SIXTY percent off your Babbel subscription—but only for our listeners, at Babbel dot com slash PASSION.Stop hair loss before it's gone for good. Hims has everything you need to regrow hair. Start your free online visit today at “Hims dot com slash PASSIONSTRUCK.”Quince brings luxury products like Mongolian Cashmere, Italian Leather, Turkish Cotton and Washable Silk to everyone at radically low prices. Go to “Quince dot com slash PASSION” for free shipping on your order and 365-day returns.--► For information about advertisers and promo codes, go to:https://passionstruck.com/deals/JUST $0.99 FOR A LIMITED TIMEOrder a copy of my book, "Passion Struck: Twelve Powerful Principles to Unlock Your Purpose and Ignite Your Most Intentional Life," today!  Recognized as a 2024 must-read by the Next Big Idea Club, the book has won the Business Minds Best Book Award, the Eric Hoffer Award, the International Book Awards for Best Non-Fiction, the 2024 Melanie P. Smith Reader's Choice Contest by Connections eMagazine, and the Non-Fiction Book Awards Gold Medal. Don't miss the opportunity to transform your life with these powerful principles!In this episode, you will learn:The American Cancer Society has funded grants for 50 young researchers who have gone on to win the Nobel Prize.The American Cancer Society focuses on three pillars: research, patient support, and advocacy.Sedentary lifestyle and Western diets are contributing factors to the rise in cancer cases.EpiOne, a biotech startup, is pioneering early cancer detection through epigenetic signals on the DNA molecule.Early detection is crucial in improving cancer survival rates and treatment outcomes.EpiOne's technology can detect cancer signals at stage zero, allowing for early intervention and treatment.All Things Michael Marquardt: https://marquardtglobal.com/Catch More of Passion StruckCan't miss my episode withJulie Fleshman on How PanCAN Is Raising the Pancreatic Cancer Survival RateListen to my interview withDr. Lynn Matrisian on the Frontlines of Pancreatic Cancer – Education, Awareness, and ProgressWatch my episode with Bill Potts on Beat Cancer by Being Your Own Best AdvocateCatch my interview with Dr. Michael Pishvaian on Why Hope Is the Key to Fighting Pancreatic CancerLike this show? Please leave us a review here-- even one sentence helps! Consider including your Twitter or Instagram handle so we can thank you personally!

We are delighted to partner with Cortechs.ai to bring you this episode of the Prostate Health Podcast. Prostate MRI has become a valuable tool in enhancing the detection, localization, and staging of prostate cancer. However, current protocols come with various challenges, like inconsistent accuracy, a significant rate of missed clinically significant prostate cancers, and considerable variability in how different radiologists interpret the results. We are thrilled to have Brittany Hunt, the head of Prostate Business Development at Cortechs.ai, joining us on the show today to introduce OnQ Prostate, an innovative new prostate MRI solution. OnQ Prostate is an FDA-cleared software solution, designed to improve the precision, consistency, and reproducibility of prostate MRI. It will enable more accurate targeting and, ultimately, better treatment outcomes. Join us as Brittany dives into this groundbreaking new technology, highlighting its advantages for patients and urologists, and explaining how it will help connect patients, referring physicians, and radiologists far more effectively. Disclaimer: The Prostate Health Podcast is for informational purposes only. Nothing in this podcast should be construed as medical advice. By listening to the podcast, no physician-patient relationship has been formed. For more information and counseling, you must contact your personal physician or urologist with questions about your unique situation. Show Highlights: Brittany reviews some of the ongoing limitations of existing prostate MRIs Brittany explains what OnQ Prostate is How OnQ Prostate makes it much easier for prostate lesions to be seen The benefits of OnQ Prostate for urologists and their patients  How OnQ Prostate works as a software add-on for existing MRI systems The multiple advantages of using the OnQ Prostate system for prostate cancer detection Why OnQ Prostate will help to bridge the gaps between patients, referring physicians, and radiologists How OnQ Prostate will help urologists become more accurate in detecting clinically significant prostate cancer  Links:  Follow Dr. Pohlman on Twitter and Instagram - @gpohlmanmd  Get your free What To Expect Guide (or find the link on our podcast website)   Join our Facebook group  Follow Dr. Pohlman on Twitterand Instagram  Go to the Prostate Health Academy to sign up.  You can access Dr. Pohlman's free mini webinar, where he discusses his top three tips to promote men's prostate health, longevity, and quality of life here. OnQ Prostate Website   Brittany Hunt on LinkedIn  Email Brittany Hunt: bhunt@cortechs.ai 

How is AI making waves in medical diagnosis and drug discovery?Have you heard about AI-powered robotic surgeries happening worldwide?How is AI reducing inefficiencies in healthcare across many areas?How is AI enhancing patient experiences and revolutionizing medical practices?Are you curious to discover how AI can improve patient experiences and data management in healthcare?Whether you're curious to know about how AI is making an impact in healthcare, this episode is a must-watch!Hey there, tech enthusiasts!

This AI-driven incidental findings program identifies and then monitors pancreatic abnormalities to improve the quality of care to patients who are at increased risk for developing pancreatic cancer. To do so, the patient management software integrates with the electronic health record and facilitates patient identification, risk assessment, care plan tracking, patient and provider communication, outcomes recording, and registry functionality. In the 2 years following program implementation, 82 pancreatic cancers were detected from incidental findings with 65% of patients being diagnosed in earlier stages (stages I, II, and II), as well as instances of ampullary cancer, gallbladder cancer, and gastric cancer. Guest:   Russell Langan, MD, FACS, FSSO Associate Chief Surgical Officer, System Integration and Quality & Director of Surgical Oncology RWJBarnabas Health, Rutgers Cancer Institute of New Jersey, Cooperman Barnabas Medical Center Livingston, New Jersey   “There remains a knowledge gap with respect to the risk associated with pancreatic cysts. Many patients are identified to have a pancreatic cyst on an incidental scan and then told [by providers] that there's no risk. [Some] patients will then return years later with pancreatic cancer. And it's very unfortunate because we know that risk could have been addressed when it was in its precancerous state.” —Russell Langan, MD, FACS, FSSO   Hear more about this innovation at the ACCC 41st National Oncology Conference, October 9-11, 2024, in Minneapolis, Minnesota. Register today.   Additional Resources: Reimagining Healthcare for Incidental Lung Nodules Oncology Capture of ED Patients with Incidental Radiologic Findings Pancreatic Cancer and Community Engagement: A Scoping Review of the Literature Let's Win Pancreatic Cancer: A Partner for Patients and Care Teams

What if you could catch cancer in its earliest stages, when it's most treatable—would you seize that chance? Our guest today is Dr. Josh Ofman, the president of GRAIL, and he's pioneering early cancer detection in a revolutionary new way. You'll discover the cutting-edge advances in multi-cancer early detection that are transforming the fight against this swift and silent killer. You'll also learn about the full potential of the GRAIL gallery test in your proactive health management. This technology is ushering in a new era in cancer care but also signals a paradigm shift in disease prevention. Learn why yearly screenings are your best strategy in the race against cancer. Prepare to dive deep into how the latest biotech innovations could significantly extend your life span!Timestamp Highlights (00:01:03) An Unsettling Trend in Cancer Proliferation (00:04:51) Introducing Dr. Josh Ofman and the GRAIL Test (00:12:27) The Revolutionary Approach of Multi-Cancer Early Detection (00:16:32) The Shift to Biological Signals in Cancer Detection (00:21:10) The Empowering Aspect of Knowing Your Cancer Status (00:29:17) How GRAIL's Gallery Test Can Change the Paradigm of Cancer Treatment (00:33:27) The Critical Nature of Annual Cancer Screening (00:38:34) How Early Detection Affects Treatment Options and Survival (00:40:54) The Future of GRAIL in Other Disease Pathways (00:50:18) Combating Fear and Misconceptions Around Cancer (00:55:10) The Impact of Socioeconomic Factors on Cancer Incidence (00:59:42) The Pivotal Role of Data in Personalized Health Sponsors ARRC LED | The perfect device for daily home use. For more information visit arrcled.com. Leela Quantum | Visit www.LeelaQ.com/Dave for 10% Off Resources Dave Asprey's NEW Book ‘Smarter Not Harder': daveasprey.com/books GRAIL Multi-Cancer Early Detection Test: Visit www.Galleri.com/Dave to see if you're eligible for a $50 off limited-time online-only offer. GRAIL Research and Studies: grail.com/clinical-studies GRAIL on Twitter: @GRAILbio See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This episode is brought to you by Cozy Earth, Lifeforce, and Lumebox.Despite significant strides in cancer research over the past two decades, there remains a vast realm of uncertainty surrounding the impact of various cancers on individuals. Amidst the proliferation of cancer discourse on social media, distinguishing evidence-based information from conjecture can prove challenging. Today's guest is here to untangle all the complexities. Today, on The Dhru Purohit Show, Dhru sits down with Dr. Joseph Zundell to discuss the research behind cancer prevention. Dr. Zundell shares the lifestyle factors that influence the development of cancer and the cutting-edge technologies for early cancer detection. Dr. Joe Zundell received his Ph.D. in cancer biology through the University of the Sciences and The Wistar Institute in Philadelphia, PA. He has over ten years of cancer research experience as a cancer biologist. Much of his published research has focused on finding new therapies for the treatment of many different cancer types based on the epigenetic and metabolic characteristics of cancers. In this episode, Dhru and Dr. Zundell dive into (audio version / Apple Subscriber version):Technology for early detection of cancer (4:55 / 4:55)Obesity and visceral fats link to cancer (22:56 /19:30)Exercising to build muscle and for longevity (28:57 / 25:06)Protein intake and the metabolic process (35:00 / 30:23)Fasting mimicking diet before chemotherapy (47:14 / 42:17)Otto Werberg's research (53:17 / 49:39)Cancer as a metabolic disease (58:15 / 53:40)An overview of Dr. Thomas Seyfried's work and Dr. Zundell's viewpoint (1:07:07 / 1:02:08)Dr. Zundell's views on what needs additional research (1:09:43 / 1:05:09)Dr. Zundell's origin story (1:18:54 / 1:13:00)Socioeconomic status and its impact on disease (1:30:37/ 1:26:38)Rapid fire community questions (1:34:02 / 1:28:35)Also mentioned in this episode:Dr. Zundell's research Get $300 off Prenuvo at prenuvo.com/dhru (not an affiliate link)Ezra Test Fasting and Caloric Restriction in Cancer Prevention and TreatmentProfessor Valter Longo's Study Right now, get 40% off your Cozy Earth sheets. Just head over to cozyearth.com and use code DHRUP.Right now, you can save $250 on your first diagnostic and get personalized suggestions. Optimize your longevity and track your progress go to mylifeforce.com/dhru! Lumebox is offering my community $260 off their FDA-approved portable Red Light device! That's over 50% off! Go to thelumebox.com/dhru and get your Red Light device. Hosted on Acast. See acast.com/privacy for more information.

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Alex Aravanis is a leader in research and development of technologies and clinical tests utilizing the latest tools in DNA analysis and data science. In this episode, Alex delves into two interconnected topics: liquid biopsies and epigenetics. He begins by tracing the trajectory of genome sequencing and tumor sequencing, setting the stage for a detailed exploration of liquid biopsies as an early cancer detection method. The discussion encompasses key concepts such as cell-free DNA, DNA methylation, sensitivity, specificity, and the predictive values associated with liquid biopsies. Transitioning to epigenetics, Alex examines the intricate interplay of DNA methylation and aging biology and explores the possibility of using cellular reprogramming to reverse epigenetic changes that occur with aging. We discuss: Alex's background in applying engineering to problems in medicine [3:15]; A primer on human genetics, and the history and current landscape of DNA sequencing [11:00]; The advent and evolution of liquid biopsies for early detection of cancer [23:15]; The role of cell-free DNA in cancer detection: how incidental findings in non-invasive prenatal testing led to the development of liquid biopsies [40:15]; The development of a universal blood test for cancer detection and a discussion of specificity of tests [46:00]; Advancements in cell-free DNA analysis and development of a multi-cancer screening test at GRAIL [51:00]; DNA methylation explained [58:15]; Optimizing cancer detection with methylation analysis of cfDNA in small blood samples [1:02:45]; The importance of understanding sensitivity, specificity, positive predictive value, and negative predictive value in cancer screening [1:08:00]; The performance of the GRAIL Galleri test and its ability to detect various types and stages of cancer [1:21:00]; Do early cancer detection methods, like liquid biopsies, translate to improvement in overall survival? [1:27:45]; The role of epigenetics in aging [1:39:30]; How cell-free DNA methylation patterns can help identify a cancer's tissue of origin [1:45:30]; Cellular and epigenetic reprogramming and other exciting work in the field of aging [1:52:30]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube